There is a community of experts who can help you in caring for your patient with PNH. Let us find the right person to assist you in providing your patients with PNH with the best care possible.
A clinical assessment is crucial to determine the risk for morbidities and premature mortality in your patient with PNH1-4
- Monitoring of patients with small PNH clones is essential since clone size can expand rapidly and unpredictably over time.6
- In PNH, hemolysis as measured by LDH ≥1.5x ULN may increase the risk of comorbidities of an active disease process7
- Patients with PNH and hemolysis (LDH ≥1.5x ULN) are 4.8x more likely to experience premature mortality compared with the age- and sex-matched population8
Patients with PNH showing signs and symptoms of hemolysis are at an increased risk for TEs and premature mortality7
In PNH, hemolysis as measured by LDH ≥1.5x ULN may increase the risk of comorbidities of an active disease process7
— Patients with PNH and hemolysis (LDH ≥1.5x ULN) are 4.8x more likely to experience premature mortality compared with the age- and sex-matched population8
Elevated hemolysis alone, and in association with clinical symptoms, increases TE risk7
- Patients with LDH ≥1.5x ULN and 1 or more clinical symptoms such as abdominal pain and dyspnea had an increased risk of TE7
Patients are at risk for TE regardless of clone size7
- Even patients with smaller clone sizes can experience thrombosis, and there was no evidence of any association between clone size category and risk of experiencing TE (P=0.843)7
In PNH, fatigue and impaired quality of life (QoL) are independent of clone size9
- Even patients with clone size <10% experienced substantial impact on QoL9
References: 1. Hill A, et al. Br J Haematol. 2010;149(3):414-425. 2. Parker C, et al. Blood. 2005;106(12):3699-3709. 3. Weitz I, et al. Intern Med J. 2013;43(3):298-307. 4. Parker CJ. Hematology Am Soc Hematol Educ Program. 2016;2016(1):208-216. 5. Rachidi S, et al. Eur J Intern Med. 2010;21(4):260-267. 6. Young NS, et al. Blood. 2006;108(8):2509-2519. 7. Lee JW, et al. Int J Hematol. 2013;97(6):749-757. 8. Jang JH, et al. J Korean Med Sci. 2016;31(2):214-221. 9. Urbano-Ispizua A, et al. The Hematol J. 2011: 422-422.